{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-017994","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2026-05-21T12:00:10+00:00","discovered_at":"2026-05-21T12:05:00.297539+00:00","generated_at":"2026-05-21T12:13:36.011375+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioCardia CardiAMP CMI trial: +179 sec exercise tolerance, 82% fewer angina episodes at EuroPCR","bullets":["Open-label cohort results presented at EuroPCR; no treatment-emergent major adverse cardiac events.","Exercise tolerance improved by avg 179 seconds, sustained over 2-year follow-up.","Angina episodes reduced by avg 82% by 6 months after treatment.","All patients had refractory angina despite guideline-directed medical therapy and prior revascularization.","Data support continued clinical development of autologous cell therapy for chronic myocardial ischemia."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-017994","json":"https://secwatch.observer/filing/0001437749-26-017994.json","markdown":"https://secwatch.observer/filing/0001437749-26-017994.md","text":"https://secwatch.observer/filing/0001437749-26-017994.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774926017994/0001437749-26-017994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774926017994/bcda20260520_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T12:13:36.011375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}